Benjamin Tomlinson, MD
- Program Director, Hematology and Oncology, UH Cleveland Medical Center
- Assistant Professor, CWRU School of Medicine
- Specialty: Hematology and Oncology
-
Location:UH Seidman Health Campus Dr
29325 Health Campus Dr
Westlake, OH 44145
- Call: 440-617-4700
Biography: Benjamin Tomlinson, MD
Expertise
Certifications & Memberships
- Medical Oncology - American Board of Internal Medicine
- Hematology - American Board of Internal Medicine
Education
Fellowship | Hematology/Oncology
Hematology/Oncology - University Of California At Davis Comprehensive Cancer Center (2012 - 2015)
Residency | Internal Medicine
Internal Medicine - Uc Davis Medical Center (2009 - 2012)
Medical Education
Case Western Reserve University School Of Medicine (2009)
Undergraduate
Case Western Reserve University (2005)
About
Benjamin K. N. Tomlinson, MD, is a hematologist-oncologist at University Hospitals Seidman Cancer Center and an Assistant Professor of Medicine at Case Western Reserve University School of Medicine. He is board-certified in Internal Medicine, Hematology and Medical Oncology and subspecializes in malignant hematology, specifically acute leukemias and myeloid neoplasms.
Dr. Tomlinson started as faculty at the UH Seidman Cancer Center after completing his internal medicine and fellowship training at UC Davis in Sacrament California. He is a member of the malignant hematology group and also follows patients through stem cell transplants. He also serves as program director for the hematology and oncology fellowship program sponsored by University Hospitals.
Dr. Tomlinson completed his undergraduate and medical degrees at Case Western Reserve University. He maintains board certification in both Hematology and Oncology and is an active member of the American Society of Clinical Oncology, American Society of Hematology, and the American Society of Transplant and Cellular Therapy.
Dr. Tomlinson’s research interests include clinical outcomes of patients with myeloid neoplasms, novel diagnostics such as measurable residual disease, and optimizing therapeutic effects while minimizing toxicity in the treatment of both myelodysplastic syndromes and acute leukemias.
Research & Publications
Research Links
PubMed
View Research
Featured Videos
Watch to find out more about this University Hospitals provider.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Benjamin Tomlinson did not disclose any Outside Relationships with Industry.